Skip to Content

'
Fredrick B. Hagemeister, M.D.

Present Title & Affiliation

Primary Appointment

Internist and Professor of Medicine, Department of Lymphoma/Myeloma, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2032
Phone: 713-792-2860
Fax: 713-794-5656

Education & Training

Degree-Granting Education

1972 University of Texas Southwestern Medical School, Dallas, TX, MD, Medicine
1968 Stanford University, Palo Alto, CA, BS, Chemistry

Postgraduate Training

1/1977-1/1979 Clinical Fellowship, Hematology/Medical Oncology, The University of Texas MD Anderson Hospital and Tumor Institute, Houston, TX
1/1973-1/1975 Clinical Residency, Internal Medicine, Charity Hospital, New Orleans, LA
1/1972-1/1973 Clinical Internship, Internal Medicine, Charity Hospital, New Orleans, LA

Board Certifications

6/1979 American Board of Internal Medicine - Diplomate in Medical Oncology
9/1978 American Board of Internal Medicine - Diplomate in Internal Medicine

Experience/Service

Academic Appointments

Internist and Associate Professor of Medicine, Department of Lymphoma/Myeloma, Department of Lymphoma/Myeloma, UT M. D. Anderson Cancer Center, Houston, TX, 1/1997-1/1998
Associate Internist and Associate Professor of Medicine, Section of Lymphoma, Department of Hematology, Department of Hematology, UT M. D. Anderson Cancer Center, Houston, TX, 1/1984-1/1997
Associate Internist and Assistant Professor of Medicine, Section of Lymphoma, Department of Hematology, Department of Hematology, UT M. D. Anderson Cancer Center, Houston, TX, 1/1983-1/1984
Assistant Internist and Assistant Professor of Medicine, Department of Internal Medicine, Department of Internal Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 1/1980-1/1983

Administrative Appointments/Responsibilities

Chief Section, Dept. of Lymphoma, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 1/1998-1/2004
Deputy Chief, Department of Hematology, Division of Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 1/1988-1/1997

Institutional Committee Activities

Member, Credentialing, 8/2010-present

Honors and Awards

2005 The Leukemia & Lymphoma Society's Dr. John J. Kenny Award, Leukemia & Lymphoma Society
2004 Service to Mankind Award, Leukemia & Lymphoma Society

Selected Publications

Peer-Reviewed Original Research Articles
1. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin's lymphoma: A 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 5/2012. e-Pub 1/2012. PMID: 22023528.
2. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 53(1):50-6, 1/2012. e-Pub 10/24/2011. PMID: 21895545.
3. Thomas DA, O'Brien S, Faderl S, Mannig Jt Jr, Romaguera JE, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt-like lymphoma: Should these be treated as different diseases? Curr Hematol Malig Rep 6(1):58-66, 3/2011. PMID: 21191675.
4. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 123(10):935-941, 10/2010. PMID: 20920696.
5. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-208, 7/2010.
6. Morris GJ, Dotan E, Smith MR, Hagemeister FB Jr, Brereton HD. Gastric mucosa-associated lymphoid tissue lymphoma. Semin Oncol 37(3):183-7, 6/2010. PMID: 20709202.
7. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-72, 2/2010. PMID: 20166765.
8. Morschauser F, Dreyling M, Rohatiner A, Hagemeister F and Bischof-Delaloye A. Rationale for consolidation to improve progression-free survival in patinets with non-Hodgkin's lymphoma: a review of the evidence. The Oncologist 14(Suppl 2):17-29, 2009. PMID: 19819921.
9. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez MA, Romaguera JE, Hagemeister FB, Pro B.. Follicular Dendritic Cell Sarcoma: A Report of 14 Cases and a Review of the Literature. Am J Hematol 82(8)(8):725-28, 8/2007. PMID: 17373675.
10. Hagemeister FB, Luis Fayad. The FLIPI and the R-FLIPI: Are we finally ready to use them in clinical trials? Am J Hematol/Onc 6:364-68, 6/2007.
11. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2/2007. PMID: 17233846.
12. Hagemeister FB. Hodgkin's Lymphoma in the Elderly: Who is "Older" and is the Disease Really Worse in Older Patients? Oncology 21:996-1002, 2007.
13. Fayad L, Hagemeister FB. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: Newer therapies needed. Leuk Lymphoma 48:657-58, 2007.
14. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47(9):1818-21, 9/2006. PMID: 17064994.
15. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-75, 2/2005. PMID: 15613697.
16. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 10:150-9, 2/2005. PMID: 15709217.
17. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with Rituximab plus hyper-CVAD alternating with Rituximab plus high-dose Methotrexate and Cytarabine. J Clin Oncol 23(28):7013-23, 2005. e-Pub 9/2005. PMID: 16145068.
18. Romaguera JE, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol 21(1):80-84, 2005. PMID: 15687889.
19. Hagemeister FB. Stem-cell transplant for Hodgkin's lymphoma: Does choice of therapy prior to high-dose treatment matter? Nat Clin Pract Oncol 2(7):344-45, 2005. PMID: 16075792.
20. Hagemeister F, Huen A. The status of allopurinol in the management of tumor lysis syndrome: a clinical review. Cancer 11 Suppl 1:S1-10, 2005. PMID: 15835720.
21. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 10/2004. e-Pub 9/2004. PMID: 15353540.
22. Hagemeister F. Does high-dose therapy cure more patients with large cell lymphoma than standard CHOP? . Am J Onc Rev 3:68-72, 1/2004.
23. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-8, Sep-Oct, 9/2003. PMID: 12883733.
24. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98:310-4, 7/2003. PMID: 12872350.
25. Hagemeister FB. Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy. Clin Adv Hematol Oncol 1(2):120-5, 2/2003. PMID: 16224391.
26. Hagemeister F. Should we continue trials of BMT as initial therapy for aggressive lymphomas at high risk of relapse? . Am J Onc Rev 8:416-417, 1/2003.
27. Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol 49 Suppl 1:S13-20, 5/2002. e-Pub 4/2002. PMID: 12042984.
28. Hagemeister FB. Review of a randomized controlled trial of Yttruim-90-labeled Ibritumomab Tiuxetan radioimmunotherapy versus Rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Am J Oncol Rev 1:222-24, 2002.
29. Hagemeister FB. Rituximab plus hyper-CVAD for mantle cell lymphoma: Updated results. Biol Ther of Lymph 5:3-6, 2002.
30. Hagemeister, Fredrick. Treatment Options for Aggressive Lymphomas. Lymph Biol & Res 7:8, 2002.
31. Hagemeister FB, Donato M. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience. Eur J Haematol Suppl 64:8-13, 7/2001. PMID: 11486405.
32. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37-41, 12/2000. PMID: 11225999.
33. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11(1):69-72, 2000. PMID: 10690390.
34. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26(5 Suppl 14):79-87, 10/1999. PMID: 10561022.
35. Hagemeister FB. The role of ifosfamide in the treatment of lymphomas. Leuk Lymphoma 34(5-6):433-41, 8/1999. PMID: 10492066.
36. Hagemeister FB. Controversies in the management of early stage Hodgkin’s disease. Can Res Ther Control 7:259-265, 1/1999.
37. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma 32(1-2):97-106, 12/1998. PMID: 10037005.
38. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14(4):1262-8, 4/1996. PMID: 8648382.
39. Hagemeister FB, Khetan R, Allen P, McLaughlin P, Rodriguez MA, Swan F, Jr, Romaguera JE, Cabanillas F. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol 5 Suppl 2:41-6, 4/1994. PMID: 8204519.
40. Hagemeister FB, Purugganan R, Podoloff DA, Hess M, Rodriguez MA, McLaughlin P, Swan F, Jr, Romaguera JE, Cabanillas F. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 5 Suppl 2:59-63, 4/1994. PMID: 8204521.
41. Hagemeister FB, Purugganan R, Fuller L, McLaughlin P, Swan F, Jr, Romaguera J, Rodriguez M, Cabanillas F. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol 31(2 Suppl 3):36-43, 4/1994. PMID: 8073308.
42. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5 Suppl 2:73-7, 3/1994. PMID: 7515650.
43. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12(3):575-9, 3/1994. PMID: 8120556.
44. Hagemeister FB. Are alkylating agents a necessary component in the therapy of Hodgkin's disease. Leuk Lymphoma 10 Suppl:91-7, 7/1993. PMID: 7683230.
45. Hagemeister FB. Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology. Leuk Lymphoma 10 Suppl:21-7, 7/1993. PMID: 7683228.
46. Hagemeister FB, Fuller LM, Velasquez WS, McLaughlin P, Redman JR, Swan F, Rodriguez MA, North L, Dixon D, Silvermintz K, et al. Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol 2(1):25-31, 1991. PMID: 2009233.
47. Hagemeister FB, Cabanillas F, Velasquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodriguez MA, Swan F, Jr, et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol 17(6 Suppl 10):34-8; discussion 38-40, 12/1990. PMID: 2259922.
48. Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, Rodriguez MA, Tucker SL, Silvermintz K, Johnson J, et al. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 8(4):615-22, 4/1990. PMID: 2313330.
49. Hagemeister FB, Fesus SM, Lamki LM, Haynie TP. Role of the gallium scan in Hodgkin's disease. Cancer 65(5):1090-6, 3/1990. PMID: 2302660.
50. Fesus SM, Hagemeister FB, Manning J. Hodgkin disease in a patient with common variable immunodeficiency. Am J Hematol 32(2):138-42, 10/1989. PMID: 2757010.
51. Fuller LM, Hagemeister FB. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease. Recent Results Cancer Res 117:197-204, 1989. PMID: 2602645.
52. Henkelmann GC, Hagemeister FB, Fuller LM. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease. J Clin Oncol 6(8):1293-302, 8/1988. PMID: 3411342.
53. Hagemeister FB. Prognostic factors in decision-making in the clinical management of Hodgkin's disease. Hematol Oncol 6(3):257-69, Jul-Sep, 7/1988. PMID: 3042583.
54. Fuller LM, Hagemeister FB, North LB, McLaughlin P, Velasquez WS, Cabanillas F. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results. Int J Radiat Oncol Biol Phys 14(4):683-92, 4/1988. PMID: 3280532.
55. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5(4):556-61, 4/1987. PMID: 3559649.
56. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5(3):407-12, 3/1987. PMID: 3819806.
57. Pillai GN, Hagemeister FB, Velasquez WS, Sullivan JA, Johnston DA, Butler JJ, Shullenberger CC. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer 55(4):691-7, 2/1985. PMID: 2578302.
58. Fuller LM, Hagemeister FB. Diagnosis and management of Hodgkin's disease in the adult. Cancer 51(12 Suppl):2469-76, 6/1983. PMID: 6687831.
59. Hagemeister FB:. New approaches to management of stage IV Hodgkin’s disease. Cancer Bulletin 35:230-232, 1/1983.
60. Hagemeister FB, Fuller LM, Sullivan JA, Johnston D, North L, Butler JJ, Velasquez WS, Shullenberger CC. Treatment of patients with stages I and II nonmediastinal Hodgkin's disease. Cancer 50(11):2307-13, 12/1982. PMID: 6754064.
61. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60(3):693-7, 9/1982. PMID: 7104493.
62. Hagemeister FB, Fuller LM, Velasquez WS, Sullivan JA, North L, Butler JJ, Johnston DA, Shullenberger CC. Stage I and II Hodgkin's disease: Involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep 66(4):789-98, 4/1982. PMID: 7074649.
63. Hagemeister FB, Fuller LM, Sullivan JA, North L, Velasquez W, Conrad FG, McLaughlin P, Butler JJ, Shullenberger CC. Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy. Radiology 141(3):783-9, 12/1981. PMID: 6895415.
64. Manoukian G, Hagemeister F, McLaughline P, Fayad L, Samaniego F, Goy A, Romaguera J, Pro B, Hess M, Cabanillas F, Khouri I, Rodriguez A. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (RFND) for Patients with Relapsed Indolent Lymphoma. Journal of Clinical Oncology. Submitted.

Invited Articles
1. Hagemeister FB. Maintenance and Consolidation Strategies in Non-Hodgkin's Lymphoma: A Review of the Data. Curr Oncol Rep 12(6):395-401, 11/2010. e-Pub 9/2010. PMID: 20820960.

Abstracts
1. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez A, Neelapu S, Samaniego F, Younes A, Kwak L. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multiday Chemotherapy Regimen of Cyclophosphamide, Doxorubicon, vincristine, prednisone, +/- Rituxan (R/CHOP): Randomized, Double-blind, Placebo-Controlled Study. Blood (ASH Annual Abstracts) 118(21), 11/2011.
2. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, McLaughlin P. Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21) (#99), 11/2011.
3. Okoroji G, Silva L, Saliba R, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriael P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, and Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): Allografting vs conventional therapy. American Society of Hematology 52nd Annual Meeting Abstracts 116(21) (#3510), 11/2010.
4. Fanale M, Lai C, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu S, Shah J, Kwak L, Dong W, Reed V, Dabaja B, Popat U and Younes A. Outocmes of nodular lymphomcyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. American Society of Hematology 52nd Annual Meeting Abstracts 116(21) (#2812), 11/2010.
5. Younes A, Copeland A, Fanale M, Hagemeister F, Fayad L, Pro B, Faria S, Ji Y, Medeiros J, Berry D, and Buglio D. Phase I/II study of the novel combinationof panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. American Society of Hematology 52nd Annual Meeting Abstracts 116(21) (#3964), 11/2010.
6. Vadhan-Raj S, hagemeister F, Fayad L, Zhou X, O'Roark S, Ames K, Rodriguez MA, Fanale M, Pro B, Johnson M, McLaughlin P, Bueso-Ramos C, Younes A, Kwak L, and Romaguera J. Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. American Society of Hematology 52nd Annual Meeting Abstracts 116(21) (#1544), 11/2010.
7. Batty N, Hagemeister FB, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. 2010 ASCO Annual Meeting Abstracts (#8057), 5/2010.
8. Fowler N, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Annual Meeting Abstracts (#8036), 5/2010.
9. Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). 2010 ASCO Annual Meeting Abstracts (#8078), 5/2010.
10. Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Kwak LW, Hagemeister FB. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. 2010 ASCO Annual Meeting Abstracts (#9103), 5/2010.
11. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, Samaniego F. A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 114 (#1714), 11/2009.
12. Wang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis J, Cabanillas F, Kwak L, Romaguera J. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 114 (#2719), 11/2009.
13. Westin J, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone loss in lymphoma patients receiving frontline therapy: Urine Ntx and bone specific alkaline phosphatase provide early evidence of zoledronic acid response. Blood (ASH Annual Meeting Abstracts) 114 (#1680), 11/2009.
14. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister F. Differential JAK-STAT Pathway Activation in primary mediastinal large b-cell lymphoma: Two subgroups with differential cytokine activation patterns and predicted responses to kinase inhibitors. Blood (ASH Annual Meeting Abstracts) 114 (#968), 11/2009.
15. Copeland A, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Results of Long Follow up and Comparison to Institutional Historical Data. Journal of the American Society of Hematology 114(22):670, 11/2009.
16. Younes A, Gordon L, Kim S, Romaguera J, Copeland A, de Castro Farial S, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL). Journal of the American Society of Hematology 114(22):243, 11/2009.

Last updated: 2/15/2013